Furthermore, the spatial proteomics analysis of tumor compartments between patients with disease control status (CR/PR/SD) and patients with progression (PD) revealed that the former group had higher expressions of immune markers such as CD20 (though not statistically significant), CD40, CD68, HLA-DR, CD11c, and CD163. The gene discussed is ITGAX; the disease is neoplasm.